Sir, A 66-year-old retired school teacher presented with difficulty in finding words, amnesia for recent events, inattention, and difficulty in walking for the last 2 years. She had jerky movements of right upper and lower limbs for 1.5 years. Three months prior to admission she showed psychomotor withdrawal and in 1 month she became bradykinetic and mute. She appeared withdrawn and apathetic with markedly reduced word output. Her speech was effortful and agrammatical with impaired sentence comprehension and relatively preserved single word comprehension. She scored 11/30 on the mini-mental state examination (MMSE) and had frontal and parietal lobe dysfunction. She had marked rigidity of all four limbs, more on the right side. Focal myoclonic jerks was seen over the right upper lower limbs during rest, aggravated by action and postures. She had severe postural instability. She had prominent and asymmetric parkinsonian features with predominant rigidity. She satisfied criteria for probable corticobasal degeneration (consensus criteria 2013 [1] ). A progressive nonfluent aphasia phenotype of corticobasal degeneration was considered. However, evaluation for a rapidly progressive dementia was done. Magnetic resonance imaging (MRI) scan of brain was normal except for a small right thalamic hematoma of size 0.5 cm × 0.5 cm. Electroencephalogram (EEG), serum vasculitis profile, human immunodeficiency virus (HIV)test, vitamin B12 deficiency test, and Venereal Disease Research Laboratory (VDRL) test were negative. Cerebrospinal fluid (CSF) study showed normal protein (51 mg%) and sugar (161 mg%) levels and absent cells. CSF N-methyl-D-aspartate (NMDA) receptor antibody and paraneoplastic panel, including antineuronal antibodies (ANA-1, 2, 3), Purkinje cell cytoplasmic antibodies, anti-glial nuclear antibody (AGNA-1), amphiphysin, collapsing response mediator protein (CRMP-5), Ma, Ta, were negative. Thyroid function tests revealed normal T3 (0.98 IU), T4 (14.8 IU), and thyroid-stimulating hormone (TSH) (3.09 IU). Anti-thyroid peroxidase (TPO) antibody titers were raised to 660 units (normal value being <20 units). Antithyroglobulin antibody was negative. In presence of anti-TPO antibodies, Hashimoto's encephalopathy (HE) was diagnosed.
She received parenteral methylprednisolone (1 g/day for 5 days, through intravenous route) followed by tapering doses of oral prednisolone. Within the initial 5 days of treatment, the patient showed significant improvement. She became more cooperative for examination and was found to have ideomotor apraxia and cortical sensory loss in the right upper arm. Her speech improved dramatically and comprehension became better. She was last seen 3 months after the discharge, and her higher mental functions were almost normal and extrapyramidal signs were absent. She did not have any myoclonic jerks and had a cautious gait. Repeat anti-TPO antibody titers were reduced (198 units, normal value <20 units).
Hashimoto's encephalopathy as a treatable cause of corticobasal disease
Our patient satisfied clinical research criteria for probable sporadic corticobasal degeneration. [1] The right thalamic hematoma was small and did not have any clinical correlate. Thalamic bleeds have been reported in case of HE and are thought to be the result of a vasculitic process. [2] The high antithyroid antibody titer and good response to corticosteroid treatment confirmed the diagnosis of HE. Extrapyramidal symptoms are uncommon in HE and consist mostly of hyperkinetic movement disorders such as tremor, myoclonus, and choreoathtotic movements. However, hypokinetic movement disorders, such as micrographia [3] and rigidity, are rarely described. [4] To the best of our knowledge, this is the first report on cannabidiol (CBD) like presentation of HE.
Patients with phenotype of corticobasal disease can have varying pathologies. [5] In the series of patients with rapidly progressive dementia (RPD) described by Geswind et al. autoimmune encephalopathy was the third commonest cause. [6] Hence, investigation for HE should be done in corticobasal ganglionic degeneration (CBGD), if progression is rapid.
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Sir, Stroke-related impairments and inactivity contribute to the accelerated development of bone mass removal. [1] [2] [3] However, the extent of decrease in bone mineral density (BMD) after stroke and all factors that influence such rapid bone loss are still not sufficiently explored. The purpose of this study was to determine the extent of BMD reduction in patients after stroke and to identify risk factors for osteoporosis.
This research was designed as a cross-sectional study that included patients after a first stroke (≤1.5 years from a stroke; N = 40), who went through inhospital rehabilitation treatment. Data were gathered by the means of anamnesis and available medical documentation. Lunar densitometer was used to determine BMD. Dual X-ray absorptiometry (DXA) examination was performed at the beginning of rehabilitation treatment and at a 1-year follow-up. DXA measurement was performed by Hologic quantitative digital radiography (QDR) (Hologic Deutschland GmbH, Germany) 4500A densitometer at the lumbar spine L2-L4 segment in anteroposterior (AP) position, while the femur was analyzed at the femoral neck, trochanter, and Ward's triangle. Femoral BMD was analyzed on the paretic side of the body.
Bone density measurements were reported as g/cm 2 . T-scores (comparison with mean young adult population peak bone mass) and Z-scores (comparison with age-matched population mean bone mass) were automatically generated from the Hologic normative databases; the scores were gender-and race-matched. BMD criteria for the diagnosis of osteoporosis (BMD T-score <-2.5) and osteopenia (BMD T-score of -1 to -2.5) were used. Patients who were diagnosed with osteopenia and low serum vitamin D levels received vitamin D supplementation therapy after initial DXA examination, while osteoporotic patients received antiresorptive bone therapy (bisphosphonates).
Osteoporosis in patients with stroke:
A cross-sectional study In this study, most patients were menopausal women (82.50%; N = 33). The mean age of patients was 66.5 ± 9.8 years.
The average values of height were 157.62 ± 36.41 cm, the average values of weight were 67.15 ± 13.68 kg, and the average values of body mass index (BMI) were 25.66 ± 3.98. The most prevalent impairment was right-sided hemiparesis (65%; N = 26). We also recruited 40 consecutive age-and sex-matched healthy subjects who were free from earlier fractures, chronic diseases, and medications influencing bone metabolism (e.g., glucocorticoids, anticonvulsants, and thyroxine). Healthy subjects were selected randomly from 
